What a buyer sees
MILTENYI BIOTEC LIMITED
Manufacture of basic pharmaceutical products · Woking · 03096272
Your turnover is on public record
filedUnusual at this size, and it works in your favour: a buyer is reading your number rather than guessing at one.
What your filings show moving
How you sit in your trade
slowest tenth typical fastest tenth youEach spread is companies in the same trade and size that did publish a turnover. Creditor days are shown but not marked: neither end of that one is plainly good.
What a buyer would ask 4
- One director on the registerA buyer's first question about a company run by one person is what happens to it if that person stops. It is usually the first thing priced.
- Everyone on the board is over 60There is no one on the register a buyer can see taking the business on. That is a discount if it stays that way and a negotiating point if it changes.
- Headcount fell from 67 to 57A buyer sees the fall and not the reason. Deliberate tightening and losing people look identical on a filing.
- No website on file against the companyThe first thing anyone does with a company number is look for the business behind it. Finding nothing is its own answer.
What a buyer would like 4
- 31 years of trading on fileLongevity is the cheapest evidence there is that the business is not one contract.
- Sales per employee better than three quarters of your tradeYours is 807,846 against 162,513 for the middle of 2,152 comparable companies.
- Debtor days better than three quarters of your tradeYours is 32 against 56 for the middle of 2,030 comparable companies.
- Stock days better than three quarters of your tradeYours is 0 against 45 for the middle of 2,028 comparable companies.
What the register says
Owners
Nobody recorded with significant control.
Directors
- 65since 1995
| Year to | Filed | Turnover | Staff | Cash |
|---|---|---|---|---|
| 2025-12-31 | 2026-08-07 | £46M | 57 | £4.7M |
| 2023-12-31 | — | £29M | 67 | £2.5M |
A rough bracket, and why it is only that
0.4–0.9× salesThe turnover range is fitted on UK companies that did file one. The multiple is a published sector average from Dutch mid-market deals, not from your own numbers and not from your own market. Treat this as the opening bracket of a conversation, not a valuation.